The heterogeneity of the tumor microenvironment as essential determinant of development, progression and therapy response of pancreatic cancer

Group Young Researchers in Inflammatory … - Cancers, 2021 - mdpi.com
Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is still one of the deadliest
cancers in western countries. It is commonly diagnosed at advanced stages and most anti …

Does the microenvironment hold the hidden key for functional precision medicine in pancreatic cancer?

J Kokkinos, A Jensen, G Sharbeen, JA McCarroll… - Cancers, 2021 - mdpi.com
Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest of all
major cancers. We now know that a 'one-size-fits-all'approach when treating PDAC patients …

Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board

K Dorman, D Zhang, K Heinrich, L Reeh, L Weiss… - Targeted Oncology, 2023 - Springer
Background In pancreatic cancer, systemic treatment options in addition to chemotherapy
remain scarce, and so far only a small proportion of patients benefit from targeted therapies …

EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy

J Lundy, M Harris, J Zalcberg, A Zimet… - Frontiers in …, 2021 - frontiersin.org
Background Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer death
and lacks effective treatment options. Diagnostic endoscopic ultrasound-guided fine-needle …

Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination …

S Shoucair, JR Habib, N Pu, B Kinny-Köster… - Annals of surgical …, 2022 - Springer
Background Prognosis in pancreatic ductal adenocarcinoma (PDAC) remains poor despite
improved systemic therapies and surgical techniques. The identification of biomarkers to …

[HTML][HTML] Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant …

AV Reddy, CS Hill, S Sehgal, D Ding… - Radiation Oncology …, 2021 - ncbi.nlm.nih.gov
Purpose The purpose of this study was to determine if somatic mutations are associated with
clinical and pathologic outcomes in patients with borderline resectable pancreatic cancer …

NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer

K Jung, S Lee, HY Na, JW Kim, JC Lee, JH Hwang… - Scientific Reports, 2022 - nature.com
According to molecular profiling studies, a considerable number of patients with pancreatic
cancer harbor potentially actionable mutations. However, there are limited relevant data …

Clinico-genomic findings, molecular docking, and mutational spectrum in an understudied population with breast cancer patients from KP, Pakistan

H Ahmad, A Ali, AT Khalil, R Ali, I Khan… - Frontiers in …, 2024 - frontiersin.org
In this study, we report the mutational profiles, pathogenicity, and their association with
different clinicopathologic and sociogenetic factors in patients with Pashtun ethnicity for the …

Adequacy of EUS–guided fine-needle aspiration and fine-needle biopsy for next-generation sequencing in pancreatic malignancies: A systematic review and meta …

Y Pan, T Ran, X Zhang, X Qin, Y Zhang… - Endoscopic …, 2024 - journals.lww.com
Methods PubMed, Embase, Cochrane Library, and Web of Science were searched from
database inception to November 11, 2023. The primary outcome was the proportion of …

[HTML][HTML] Clinical study on the safety, efficacy, and prognosis of molecular targeted drug therapy for advanced gastric cancer

L Wang, W Li, Y Liu, C Zhang, W Gao… - American Journal of …, 2021 - ncbi.nlm.nih.gov
Objective: To investigate the safety, efficacy, and prognosis of advanced gastric cancer
patients treated with molecular targeted drug therapy. Methods: A total of 200 patients with …